<DOC>
	<DOCNO>NCT01531374</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Medtronic CoreValve® System treatment symptomatic severe aortic stenosis subject predict high risk high risk aortic valve surgery .</brief_summary>
	<brief_title>Safety Efficacy Continued Access Study Medtronic CoreValve® System Treatment Symptomatic Severe Aortic Stenosis Very High Risk Subjects High Risk Subjects Who Need Aortic Valve Replacement</brief_title>
	<detailed_description />
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . High Risk : Subject must comorbidities one cardiologist two cardiac surgeon agree predict risk operative mortality ≥15 % ( predict operative mortality serious , irreversible morbidity risk &lt; 50 % ) 30 day . OR Extreme Risk : Subject must comorbidities one cardiologist two cardiac surgeon agree medical factor preclude operation , base conclusion probability death serious morbidity exceed probability meaningful improvement . Specifically , predict operative risk death serious , irreversible morbidity ≥ 50 % 30 day . 2 . Subject senile degenerative aortic valve stenosis : Mean gradient &gt; 40 mmHg , jet velocity great 4.0 m/sec either rest dobutamine stress echocardiogram , simultaneous pressure recording cardiac catheterization ( either rest dobutamine stress ) , AND An initial aortic valve area ≤ 0.8 cm2 ( aortic valve area index ≤ 0.5 cm2/m2 ) rest echocardiogram simultaneous pressure recording cardiac catheterization 3 . Subject symptomatic his/her aortic valve stenosis , demonstrate New York Heart Association ( NYHA ) Functional Class II great . 4 . The subject subject 's legal representative inform nature trial , agree provision provide write informed consent approve IRB respective clinical site . 5 . The subject treating physician agree subject return require postprocedure followup visit . Clinical 1 . Evidence acute myocardial infarction ≤ 30 day intend treatment . 2 . Any percutaneous coronary peripheral interventional procedure perform within 30 day prior MCS TAVI procedure include bare metal drug elute stent . 3 . Blood dyscrasia define : leukopenia ( WBC &lt; 1000mm3 ) , thrombocytopenia ( platelet count &lt; 50,000 cells/mm3 ) , history bleed diathesis coagulopathy . 4 . Untreated clinically significant coronary artery disease require revascularization . 5 . Cardiogenic shock manifest low cardiac output , vasopressor dependence , mechanical hemodynamic support . 6 . Need emergency surgery reason . 7 . Severe ventricular dysfunction leave ventricular ejection fraction ( LVEF ) &lt; 20 % measure rest echocardiogram . 8 . Recent ( within 6 month ) cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) . 9 . End stage renal disease require chronic dialysis creatinine clearance &lt; 20 cc/min . 10 . Active GI bleeding would preclude anticoagulation . 11 . A known hypersensitivity contraindication follow adequately premedicated : Aspirin Heparin ( HIT/HITTS ) bivalirudin Nitinol ( titanium nickel ) Ticlopidine clopidogrel Contrast medium 12 . Ongoing sepsis , include active endocarditis . 13 . Subject refuse blood transfusion . 14 . Life expectancy &lt; 12 month due associate noncardiac comorbid condition . 15 . Other medical , social , psychological condition opinion Investigator precludes subject appropriate consent . 16 . Severe dementia ( result either inability provide inform consent trial/procedure , prevents independent lifestyle outside chronic care facility , fundamentally complicate rehabilitation procedure compliance followup visit ) . 17 . Currently participate investigational drug another device trial . 18 . Symptomatic carotid vertebral artery disease . Anatomical 19 . High Risk : Native aortic annulus size &lt; 20 mm &gt; 29 mm per baseline diagnostic imaging ( 23mm valve enrollment completion/closure CoreValve® US Pivotal TrialHigh Risk Cohort ) OR Extreme Risk : Native aortic annulus size &lt; 18 mm &gt; 29 mm per baseline diagnostic imaging . ( High risk extreme risk upon 23mm valve enrollment completion/closure CoreValve® US Pivotal TrialHigh Risk Cohort ) 20 . Preexisting prosthetic heart valve position . 21 . Mixed aortic valve disease ( aortic stenosis aortic regurgitation predominant aortic regurgitation ( 34+ ) ) . 22 . Moderate severe ( 34+ ) severe ( 4+ ) mitral severe ( 4+ ) tricuspid regurgitation . 23 . Moderate severe mitral stenosis . 24 . Hypertrophic obstructive cardiomyopathy . 25 . Echocardiographic evidence new untreated intracardiac mass , thrombus vegetation . 26 . Severe basal septal hypertrophy outflow gradient . 27 . Aortic root angulation ( angle plane aortic valve annulus horizontal plane/vertebrae ) &gt; 70° ( femoral leave subclavian/axillary access ) &gt; 30° ( right subclavian/axillary access ) . 28 . Ascending aorta diameter &gt; 43 mm aortic annulus diameter 2329 mm ; ascend aortic diameter &gt; 40 mm aortic annulus diameter 2023 mm ; ascend aorta diameter &gt; 34 mm aortic annulus diameter 1820 mm ( Extreme Risk 23 mm valve enrollment completion/closure CoreValve® US Pivotal TrialHigh Risk Cohort ) . 29 . Congenital bicuspid unicuspid valve verify echocardiography . 30 . Sinus valsalva anatomy would prevent adequate coronary perfusion . Vascular 31 . Transarterial access able accommodate 18Fr sheath .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Valvular Heart Disease</keyword>
	<keyword>Critical Aortic Stenosis</keyword>
	<keyword>Severe Aortic Stenosis</keyword>
	<keyword>Extreme Risk</keyword>
	<keyword>High Risk</keyword>
	<keyword>Aortic Valve Replacement</keyword>
</DOC>